Please login to the form below

Not currently logged in
Email:
Password:

rituximab

This page shows the latest rituximab news and features for those working in and with pharma, biotech and healthcare.

Genentech agrees trade secret theft settlement with Taiwan’s JHL

Genentech agrees trade secret theft settlement with Taiwan’s JHL

News of the spat emerged last year, with Genentech accusing JHL of stealing its confidential and proprietary information in order to guide the development of biosimilar versions of Rituxan (rituximab), Herceptin

Latest news

More from news
Approximately 9 fully matching, plus 136 partially matching documents found.

Latest Intelligence

  • The sound of silence puts the squeeze on generics and biosimilars The sound of silence puts the squeeze on generics and biosimilars

    drugs - from Adalimumab to Rituximab - go off-patent and boost savings across eight European nations to 33.4bn over the next three years.

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab). .

  • Deal Watch December 2016 Deal Watch December 2016

    Sanofi's payments to JHL, the Taiwanese manufacturer of a rituximab biosimilar, total $101m upfront for the China market alone; 30% of the headline figure.

  • Deal Watch November 2016 Deal Watch November 2016

    By destroying B cells, rituximab is used to treat diseases characterised by excessive numbers of B cells, overactive B cells or dysfunctional B cells including many lymphomas, leukaemias, transplant rejection and ... In May this year Sandoz announced

  • Deal Watch October 2016 Deal Watch October 2016

    Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    His previous business experience includes several oncology-related positions at Biogen Idec, including team leader for Rituxan (rituximab), as well as commercial positions at Amgen,.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).

  • Biosimilars: Getting the flock to market

    The greatest attraction, naturally, is high-revenue anti-TNF agents like MabThera (rituximab) and Humira (adalimumab), for many years the world's most valuable drug.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics